US 11,970,514 B2
Neuroactive steroids and their methods of use
Maria Jesus Blanco-Pillado, Arlington, MA (US); Francesco G. Salituro, Marlborough, MA (US); and Marshall Lee Morningstar, Framingham, MA (US)
Assigned to Sage Therapeutics, Inc., Cambridge, MA (US)
Filed by SAGE THERAPEUTICS, INC., Cambridge, MA (US)
Filed on Jun. 13, 2023, as Appl. No. 18/334,124.
Application 18/334,124 is a continuation of application No. 17/311,056, previously published as PCT/US2019/064692, filed on Dec. 5, 2019.
Claims priority of provisional application 62/775,470, filed on Dec. 5, 2018.
Prior Publication US 2023/0322847 A1, Oct. 12, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07J 43/00 (2006.01); C07J 41/00 (2006.01)
CPC C07J 43/003 (2013.01) [C07J 41/0044 (2013.01); C07J 41/0094 (2013.01)] 20 Claims
 
1. A compound of Formula (I-l):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
each of R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, and R12b is hydrogen;
R3a is ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, cyclopropyl, or cyclopropylmethyl;
R18 is methyl;
R19 is hydrogen, methyl, or ethyl;
RY is methyl;
each RD is hydrogen;
q is 0, 1, 2, 3, 4, or 5; and
R55a and R55b join together with their intervening atoms to form

OG Complex Work Unit Chemistry
 wherein
p is 1, and
Ra is —CN.